We were told possibly 30-40% since we are not getting the ADHD drug and the Oncology product is at least 5 years out and that's IF it doesn't get pushed back by the FDA (which always happens). Symproic is so far behind forecast its sick. The Opioid market is not the market to be in these days. It will continue to decline as government puts more prescribing restrictions on it. Therefore, Hysingla and OxyContin will continue to drop in RX's and Butrans will continue to stay flat and not make the company profit.
Purdue should've never hired as many reps as they have just to overlap and copromote. It wasn't needed and not enough TRUE targets. This was foolish for our market and now several people will be out of a job due to ignorance.
It was a depressing meeting and I don't think people (you) should be left in the dark due to Purdues bad business decisions and find yourself shocked and without a job.